Literature DB >> 15557324

Transient versus sustained phosphorylation and nuclear accumulation of ERKs underlie anti-versus pro-apoptotic effects of estrogens.

Jin-Ran Chen1, Lilian I Plotkin, José Ignacio Aguirre, Li Han, Robert L Jilka, Stavroula Kousteni, Teresita Bellido, Stavros C Manolagas.   

Abstract

Sex steroids exert anti-apoptotic effects on osteoblasts/osteocytes but exert pro-apoptotic effects on osteoclasts, in both cases requiring activation of the extracellular signal-regulated kinases (ERKs). To explain the mechanistic basis of this divergence, we searched for differences in the kinetics of phosphorylation and/or in the subcellular localization of ERKs in response to 17beta-estradiol in the two cell types. In contrast to its transient effect on ERK phosphorylation in osteocytic cells (return to base line by 30 min), 17beta-estradiol-induced ERK phosphorylation in osteoclasts was sustained for at least 24 h following exposure to the hormone. Conversion of sustained ERK phosphorylation to transient, by means of cholera toxin-induced activation of the adenylate cyclase/cAMP/protein kinase A pathway, abrogated the pro-apoptotic effect of 17beta-estradiol on osteoclasts. Conversely, prolongation of ERK activation in osteocytes, by means of leptomycin B-induced inhibition of ERK export from the nucleus or overexpression of a green fluorescent protein-ERK2 mutant that resides permanently in the nucleus, converted the anti-apoptotic effect of 17beta-estradiol to a pro-apoptotic one. These findings indicate that the kinetics of ERK phosphorylation and the length of time that phospho-ERKs are retained in the nucleus are responsible for pro-versus anti-apoptotic effects of estrogen on different cell types of bone and perhaps their many other target tissues.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15557324     DOI: 10.1074/jbc.M411530200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

Review 1.  Integration of the extranuclear and nuclear actions of estrogen.

Authors:  Ellis R Levin
Journal:  Mol Endocrinol       Date:  2005-02-10

2.  Estrogen suppresses uterine epithelial apoptosis by inducing birc1 expression.

Authors:  Yan Yin; Wei-Wei Huang; Congxing Lin; Hong Chen; Alex MacKenzie; Liang Ma
Journal:  Mol Endocrinol       Date:  2007-09-27

3.  An anticancer agent icaritin induces sustained activation of the extracellular signal-regulated kinase (ERK) pathway and inhibits growth of breast cancer cells.

Authors:  YuMing Guo; XinTian Zhang; Jun Meng; Zhao-Yi Wang
Journal:  Eur J Pharmacol       Date:  2011-03-01       Impact factor: 4.432

4.  Silencing of CDK2, but not CDK1, separates mitogenic from anti-apoptotic signaling, sensitizing p53 defective cells for synthetic lethality.

Authors:  Tatyana S Nekova; Susanne Kneitz; Hermann Einsele; Ralf Bargou; Gernot Stuhler
Journal:  Cell Cycle       Date:  2016-11-10       Impact factor: 4.534

Review 5.  The role of estrogen and androgen receptors in bone health and disease.

Authors:  Stavros C Manolagas; Charles A O'Brien; Maria Almeida
Journal:  Nat Rev Endocrinol       Date:  2013-09-17       Impact factor: 43.330

Review 6.  Is interaction between age-dependent decline in mechanical stimulation and osteocyte-estrogen receptor levels the culprit for postmenopausal-impaired bone formation?

Authors:  R Sapir-Koren; G Livshits
Journal:  Osteoporos Int       Date:  2012-11-15       Impact factor: 4.507

Review 7.  From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis.

Authors:  Stavros C Manolagas
Journal:  Endocr Rev       Date:  2010-01-05       Impact factor: 19.871

8.  The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone.

Authors:  Marta Martin-Millan; Maria Almeida; Elena Ambrogini; Li Han; Haibo Zhao; Robert S Weinstein; Robert L Jilka; Charles A O'Brien; Stavros C Manolagas
Journal:  Mol Endocrinol       Date:  2010-01-06

9.  Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest.

Authors:  Q K Y Chan; H-M Lam; C-F Ng; A Y Y Lee; E S Y Chan; H-K Ng; S-M Ho; K-M Lau
Journal:  Cell Death Differ       Date:  2010-03-05       Impact factor: 15.828

Review 10.  Osteoarthritis associated with estrogen deficiency.

Authors:  Jorge A Roman-Blas; Santos Castañeda; Raquel Largo; Gabriel Herrero-Beaumont
Journal:  Arthritis Res Ther       Date:  2009-09-21       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.